CHE insider sale notice: 556 common shares planned for 07/31/2025
Rhea-AI Filing Summary
Chemed Corporation (CHE) notice of proposed sale reports an intended sale of 556 common shares with an aggregate market value of $232,410.94, representing holdings out of 14,571,695 shares outstanding. The approximate date of sale is 07/31/2025 and the transaction lists Merrill Lynch, 401 E Las Olas Blvd., Fort Lauderdale, FL as the broker and the NYSE as the exchange. The shares were acquired as stock awards: 262 shares on 05/16/2022 and 294 shares on 05/15/2023, with payment recorded on the acquisition dates. The filer indicates no securities sold in the past three months and includes the standard representation that they are unaware of undisclosed material adverse information about the issuer.
Positive
- Transparent disclosure of the intended sale including broker, exchange, and aggregate market value
- Acquisition details provided showing the shares were received as stock awards with dates and amounts
Negative
- None.
Insights
TL;DR: Routine insider sale notice showing a small planned disposition of vested stock awards, with no recent sales reported.
The Form 144 discloses a proposed sale of 556 common shares valued at $232,410.94, executed through Merrill Lynch and scheduled for 07/31/2025. The holdings derive from two stock awards vested in 2022 and 2023. There are no reported sales in the prior three months, indicating this filing documents a planned, rather than recurring, disposition. For investors, this appears procedural and consistent with normal post-vesting sales by insiders, with no additional operational or financial data disclosed.
TL;DR: Compliance-focused filing that meets disclosure requirements under Rule 144; contains standard attestations.
The notice includes the required acquisition details, broker information, and a signer representation regarding material undisclosed information, satisfying Rule 144 procedural disclosures. The acquisition types are listed as stock awards with payment dates matching grant/vesting dates. The absence of prior three-month sales simplifies aggregation considerations. From a governance perspective, the filing reflects routine insider transparency without revealing governance or control changes.